Our study not only endorsed the therapeutic potential of peripheral CB1R antagonism for clinical translation but also demonstrated the benefit of using the multi‐omics‐based framework to identify druggable targets for pharmacological intervention and developing rational combination therapies using the bleomycin‐induced PF model. This evidence concerns the gene CNR1 and pemphigus foliaceus.